Authors

Roger B. Cohen, MD

Latest:

There is a Significant Unmet Need in MTC

Joseph D. Khoury, MD

Latest:

Dr. Khoury on the Importance of Differentiating Between BPDCN and AML

Joseph D. Khoury, MD, discusses the importance of differentiating between blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia.

Danielle E. Hammond, MD, FRCP(C)

Latest:

Small Clones, Outsized Consequences: The Many Faces of Clonal Hematopoiesis

Danielle E. Hammond, MD, FRCP(C), of The University of Texas MD Anderson Cancer Center, discusses the many faces of clonal hematopoiesis.

Vinai Gondi, MD

Latest:

Dr Gondi on Prophylactic Cranial Irradiation With Hippocampal Avoidance in SCLC

Vinai Gondi, MD, discusses efficacy and safety findings from the phase 2/3 NRG-CC003 trial of prophylactic cranial irradiation in patients with small cell lung cancer.

Karim Masrouha, MD

Latest:

Dr. Masrouha on the Challenges of Surgical Removal of Chordoma Tumors

Karim Masrouha, MD, discusses the challenges of surgically removing chordoma tumors.

James Chih-Hsin Yang, MD

Latest:

Dr Yang on the Results of the KEYNOTE-789 Trial in EGFR-mutant NSCLC

James Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.

Michael Jain, MD

Latest:

Dr Jain on the Impact of CD39+ T Cells on CAR T-Cell Phenotype

Michael Jain, MD, discusses the importance of evaluating the impact of lymphoma-associated CD39-positive T cells on CAR T-cell phenotypes.

Hemali Batra-Sharma, M

Latest:

Dr Batra-Sharma on Conducting a Clinicopathologic Investigation Into Metaplastic Breast Cancer

Hemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Christiane Querfeld, MD, PhD

Latest:

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma

Sander Bach, MD, PhD

Latest:

Dr. Bach on Examining ctDNA in CRC

Sander Bach, MD, PhD, discusses research examining circulating tumor DNA in colorectal cancer.

Kelly Weaver, NP, DNP

Latest:

The Potential of Modified Treatment Regimens in AYA ALL

Experts on AYA ALL discuss the potential applicability of modified treatment regimens and the importance of multidisciplinary collaboration to meet the unique needs of patients.

Rhonda Cooper

Latest:

Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy

Camidge and Cooper discuss Cooper’s career as a hospital chaplain, the focus of her writing, and the importance of meeting patients where they are.

Firas El Chaer, MD

Latest:

Dr. El Chaer on the Role of Next-Generation Sequencing in MPNs

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Laura Huppert, MD

Latest:

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

Matthew J. Baker, PhD

Latest:

Dr Baker on the EMBRACE Trial of the Dxcover Liquid Biopsy in Brain Cancer

Matthew J. Baker, PhD, discusses the ongoing investigation of the Dxcover Liquid Biopsy for patients with brain cancer in the EMBRACE study.

Naoki Niikura, MD, PhD

Latest:

Dr Niikura on T-DXd in Patients With HER2+ Breast Cancer With Brain Metastases and Leptomeningeal Disease

Naoki Niikura, MD, PhD, discusses the impact of treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer with brain metastases and/or leptomeningeal disease, as evaluated in the real-world ROSET-BM study in Japan.

Kathryn Hitchcock, MD, PhD

Latest:

Dr Hitchcock on Potential Clinical Implications of the ERAsur Trial in Limited mCRC

Kathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer

Sarah E. S. Leary, MD, MS

Latest:

Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma

Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

Mark R. Albertini, MD

Latest:

Stage Is Set for Continued Progress in the Melanoma Clinic

Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.

Manisha Palta, MD

Latest:

Dr. Palta on the Clinical Implications of the NRG/RTOG 1112 Trial in HCC

Manisha Palta, MD, discusses the clinical implications of the phase 3 NRG/RTOG 1112 trial in patients with locally advanced hepatocellular carcinoma.